Clinical outcomes of weekly adalimumab in refractory non-infectious paediatric uveitis and the role of serum drug levels and anti-adalimumab antibodies - Takeaways - MDSpire

Clinical outcomes of weekly adalimumab in refractory non-infectious paediatric uveitis and the role of serum drug levels and anti-adalimumab antibodies

  • By

  • Amelia Rees

  • Raheej Khan

  • Jessy Choi

  • Clare Nash

  • Daniel Hawley

  • Sasa Pockar

  • Shiao Wei Wong

  • Guilia Varnier

  • Vinod Sharma

  • Alice Chieng

  • Jane Ashworth

  • May 29, 2026

  • 0 min

Share

  • 1

    Weekly adalimumab (ADA) treatment shows promise for children with refractory non-infectious pediatric uveitis (pCAU) after biweekly dosing fails.

  • 2

    In a study of 15 pediatric patients, 66.7% achieved disease control within three months of escalating to weekly ADA.

  • 3

    The majority of patients had juvenile idiopathic arthritis (JIA)-associated uveitis, highlighting the systemic link to pCAU.

  • 4

    Serum drug levels and anti-adalimumab antibody titres were monitored to guide treatment decisions and assess efficacy.

  • 5

    This study contributes to limited evidence supporting weekly ADA as an off-label treatment strategy for refractory pediatric uveitis.

Original Source(s)

Clinical outcomes of weekly adalimumab in refractory non-infectious paediatric uveitis and the role of serum drug levels and anti-adalimumab antibodies

  • by Amelia Rees, Raheej Khan, Jessy Choi, Clare Nash, Daniel Hawley, Sasa Pockar, Shiao Wei Wong, Guilia Varnier, Vinod Sharma, Alice Chieng, Jane Ashworth

  • May 29, 2026

Related Content

Retinal AI Predicts Neonatal Lung Disease

Retinal scans already performed in the NICU could flag infants at risk for serious lung disease before standard diagnosis

Systemic Corticosteroids as an Adjunct Therapy in Pediatric Orbital Cellulitis: A Comprehensive Review and Meta-Analysis

Navigated hepatic tumor resection using intraoperative ultrasound imaging